Close Search

Honors & Awards


  • $460.50
    David Margolis
    Tensile and Torsional Testing of Composite Ceramic Polymer Materials (WAESO)
    Orthopedic Surgery
    Research Training
  • $944,104.75
    Monika Schmelz
    ANCHOR- Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions (HSIL)
  • $1,509,452.00
    Erika Eggers
    Retinal Neuronal Signaling in Early Diabetes



Meet the Expert: Carlos Gonzales, MD, FAAFP

In The Media

  • The relatively low number of West Nile cases has been a roadblock for development of a vaccine. In Phase III clinical trials, a significant number of individuals has to be infected and enrolled in order for a vaccine or treatment to demonstrate efficacy. Only a proven effective vaccine will be approved for use in humans, explained Deepta Bhattacharya, PhD, a professor of immunobiology at the College of Medicine – Phoenix. “That was one of the reasons why the SARS-CoV-2 vaccines were able to be deployed so quickly: at the time Pfizer and Moderna were testing the vaccine, there was a ton of community spread,” Dr. Bhattacharya said.

  • National Geographic - October 19

    Many factors weaken the aging immune system. But vaccines—and booster doses—do offer protection from hospitalization and death. Experts say they still don’t have an adequate explanation for why older people were more susceptible to COVID-19 even before vaccines were available. “It’s just one of the great mysteries of the virus,” says Deepta Bhattacharya, PhD, professor of immunobiology at the College of Medicine – Tucson.

  • - October 18

    Nicola Finley, MD, a board-certified internal medicine physician and adjunct faculty member at the Mel and Enid Zuckerman College of Public Health, will lead a panel on how the pandemic exposed inequities in both health care and wellness and how that will be tackled in the future.


Grand Rounds